After markets closed on Wednesday, Relmada Therapeutics, Inc. (Nasdaq: RLMD) delivered its financial results for the second quarter ending June 30, 2024. The company does not have revenue to report at this time. Relmada told investors that the net loss for the quarter was $17.8 million, or $0.59 per basic and diluted share, compared …
Category: Psychedelics
The Daily Hit: August 6, 2024
The Daily Hit is a recap of the top financial news stories for Tuesday, August 6, 2024. On the Site Ohio welcomes recreational marijuana sales with excitement, celebration Earlier today, adult-use recreational cannabis went on sale at dozens of dispensaries across Ohio, nearly nine months after voters approved Issue 2. …
Survey: Investor interest in psychedelic stocks grows, but few buy in
A new survey suggests investors are interested in psychedelic stocks, but that isn’t translating into growing investment just yet. The study, conducted by Quantum Research Group LLC on behalf of Incannex Healthcare Inc. (Nasdaq: IXHL), found that 66% of stock investors are “psychedelic-friendly,” meaning they have either invested in psychedelic …
Incannex Healthcare gets FDA nod for Phase 2 trial
Incannex Healthcare Inc. (Nasdaq: IXHL) has received approval from the US Food and Drug Administration (FDA) to begin its Phase 2 clinical trial studying psilocybin on patients with generalized anxiety disorder (GAD). The trial uses Incannex’s psilocybin compound known as PSX-001. The psilocybin treatment is also accompanied by psychotherapy. Incannex …